{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:27:37Z","timestamp":1790904457626,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013560","name":"GBS\/CIDP Foundation International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013560","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CSL Behring"},{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To assess clinical outcome in treatment-naive patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included adult treatment-naive patients participating in the prospective International CIDP Outcome Study (ICOS) that fulfilled the European Federation of Neurological Societies\/Peripheral Nerve Society (EFNS\/PNS) diagnostic criteria for CIDP. Patients were grouped based on initial treatment with (1) intravenous immunoglobulin (IVIg), (2) corticosteroid monotherapy or (3) IVIg and corticosteroids (combination treatment). Outcome measures included the inflammatory Rasch-built overall disability scale (I-RODS), grip strength, and Medical Research Council (MRC) sum score. Treatment response, treatment status, remissions (improved and untreated), treatment changes, and residual symptoms or deficits were assessed at 1\u00a0year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty patients were included of whom 18 (45%) initially received IVIg, 6 (15%) corticosteroids, and 16 (40%) combination treatment. Improvement on\u2009\u2265\u20091 of the outcome measures was seen in 31 (78%) patients. At 1\u00a0year, 19 (48%) patients were still treated and fourteen (36%) patients were in remission. Improvement was seen most frequently in patients started on IVIg (94%) and remission in those started on combination treatment (44%). Differences between groups did not reach statistical significance. Residual symptoms or deficits ranged from 25% for neuropathic pain to 96% for any sensory deficit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Improvement was seen in most patients. One year after the start of treatment, more than half of the patients were untreated and around one-third in remission. Residual symptoms and deficits were common regardless of treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-021-10677-5","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T05:03:01Z","timestamp":1624683781000},"page":"945-955","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical outcome of CIDP one\u00a0year after start of treatment: a prospective cohort study"],"prefix":"10.1007","volume":"269","author":[{"given":"S. R. M.","family":"Bus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Broers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"Lucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bunschoten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. G. A.","family":"van Lieverloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Adrichem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"van Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. F.","family":"Lingsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. S.","family":"Goedee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. L.","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-0776","authenticated-orcid":false,"given":"F.","family":"Eftimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ICOS Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"issue":"3","key":"10677_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"PY Van den Bergh","year":"2010","unstructured":"Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, Koski CL, Leger JM, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA, van Schaik IN, European Federation of Neurological S, Peripheral Nerve S (2010) European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2014first revision. Eur J Neurol 17(3):356\u2013363. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02930.x","journal-title":"Eur J Neurol"},{"issue":"3\u20134","key":"10677_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000494291","volume":"52","author":"MC Broers","year":"2019","unstructured":"Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC (2019) Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology 52(3\u20134):161\u2013172. https:\/\/doi.org\/10.1159\/000494291","journal-title":"Neuroepidemiology"},{"issue":"9","key":"10677_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","volume":"90","author":"HC Lehmann","year":"2019","unstructured":"Lehmann HC, Burke D, Kuwabara S (2019) Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry 90(9):981\u2013987. https:\/\/doi.org\/10.1136\/jnnp-2019-320314","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10677_CR4","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1093\/brain\/awaa265","volume":"143","author":"F Eftimov","year":"2020","unstructured":"Eftimov F, Lucke IM, Querol LA, Rajabally YA, Verhamme C (2020) Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 143(11):3214\u20133224. https:\/\/doi.org\/10.1093\/brain\/awaa265","journal-title":"Brain"},{"issue":"2","key":"10677_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27046","volume":"63","author":"AM Stino","year":"2021","unstructured":"Stino AM, Naddaf E, Dyck PJ, Dyck PJB (2021) Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach. Muscle Nerve 63(2):157\u2013169. https:\/\/doi.org\/10.1002\/mus.27046","journal-title":"Muscle Nerve"},{"key":"10677_CR6","doi-asserted-by":"publisher","first-page":"CD002062","DOI":"10.1002\/14651858.CD002062.pub3","volume":"1","author":"RA Hughes","year":"2015","unstructured":"Hughes RA, Mehndiratta MM (2015) Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 1:CD002062. https:\/\/doi.org\/10.1002\/14651858.CD002062.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"10677_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003906.pub4","author":"MM Mehndiratta","year":"2015","unstructured":"Mehndiratta MM, Hughes RA, Pritchard J (2015) Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003906.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"10677_CR8","doi-asserted-by":"publisher","first-page":"CD010369","DOI":"10.1002\/14651858.CD010369.pub2","volume":"1","author":"AL Oaklander","year":"2017","unstructured":"Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH (2017) Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev 1:CD010369. https:\/\/doi.org\/10.1002\/14651858.CD010369.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"10677_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001797.pub3","author":"F Eftimov","year":"2013","unstructured":"Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN (2013) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001797.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"10677_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2018.11.031","volume":"397","author":"D Gelinas","year":"2019","unstructured":"Gelinas D, Katz J, Nisbet P, England JD (2019) Current practice patterns in CIDP: a cross-sectional survey of neurologists in the United States. J Neurol Sci 397:84\u201391. https:\/\/doi.org\/10.1016\/j.jns.2018.11.031","journal-title":"J Neurol Sci"},{"key":"10677_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12399","author":"MC Broers","year":"2020","unstructured":"Broers MC, van Doorn PA, Kuitwaard K, Eftimov F, Wirtz PW, Goedee S, Lingsma HF, Jacobs BC (2020) Diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in clinical practice: a survey among Dutch neurologists. J Peripher Nerv Syst. https:\/\/doi.org\/10.1111\/jns.12399","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"10677_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/s1474-4422(07)70329-0","volume":"7","author":"RAC Hughes","year":"2008","unstructured":"Hughes RAC, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung H-P, Latov N, Merkies ISJ, van Doorn PA (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7(2):136\u2013144. https:\/\/doi.org\/10.1016\/s1474-4422(07)70329-0","journal-title":"Lancet Neurol"},{"issue":"7","key":"10677_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archneurol.2010.105","volume":"67","author":"N Latov","year":"2010","unstructured":"Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, Hartung HP, Hughes RA, Merkies IS, van Doorn PA, Group I-CCES (2010) Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 67(7):802\u2013807. https:\/\/doi.org\/10.1001\/archneurol.2010.105","journal-title":"Arch Neurol"},{"issue":"10","key":"10677_CR14","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1136\/jnnp-2017-316427","volume":"88","author":"S Kuwabara","year":"2017","unstructured":"Kuwabara S, Mori M, Misawa S, Suzuki M, Nishiyama K, Mutoh T, Doi S, Kokubun N, Kamijo M, Yoshikawa H, Abe K, Nishida Y, Okada K, Sekiguchi K, Sakamoto K, Kusunoki S, Sobue G, Kaji R, Glovenin ICSG (2017) Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 88(10):832\u2013838. https:\/\/doi.org\/10.1136\/jnnp-2017-316427","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10677_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s1474-4422(10)70021-1","volume":"9","author":"IN van Schaik","year":"2010","unstructured":"van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JCH, Vogels OJM, Hadden RDM, Kleine BU, van Norden AGW, Verschuuren JJGM, Dijkgraaf MGW, Vermeulen M (2010) Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 9(3):245\u2013253. https:\/\/doi.org\/10.1016\/s1474-4422(10)70021-1","journal-title":"Lancet Neurol"},{"issue":"6","key":"10677_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s1474-4422(12)70093-5","volume":"11","author":"E Nobile-Orazio","year":"2012","unstructured":"Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Macchia R, Cavaletti G, Giannini F, Sabatelli M (2012) Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 11(6):493\u2013502. https:\/\/doi.org\/10.1016\/s1474-4422(12)70093-5","journal-title":"Lancet Neurol"},{"issue":"7","key":"10677_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/jnnp-2013-307515","volume":"86","author":"E Nobile-Orazio","year":"2015","unstructured":"Nobile-Orazio E, Cocito D, Jann S, Uncini A, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Cavaletti G, Giannini F, Sabatelli M, Beghi E, Group IMCT (2015) Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry 86(7):729\u2013734. https:\/\/doi.org\/10.1136\/jnnp-2013-307515","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10677_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS (2016) Long-term side effects of glucocorticoids. Expert Opin Drug Saf 15(4):457\u2013465. https:\/\/doi.org\/10.1517\/14740338.2016.1140743","journal-title":"Expert Opin Drug Saf"},{"key":"10677_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14096","author":"ME Adrichem","year":"2019","unstructured":"Adrichem ME, Bus S, Wieske L, Mohammed H, Verhamme C, Hadden R, van Schaik IN, Eftimov F (2019) Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC-protocol); a prospective pilot study. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.14096","journal-title":"Eur J Neurol"},{"issue":"1","key":"10677_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jns.12296","volume":"24","author":"C Bunschoten","year":"2019","unstructured":"Bunschoten C, Eftimov F, van der Pol WL, Jacobs BC, Consortium I (2019) International chronic inflammatory demyelinating polyneuropathy outcome study (ICOS): Protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome. J Peripher Nerv Syst 24(1):34\u201338. https:\/\/doi.org\/10.1111\/jns.12296","journal-title":"J Peripher Nerv Syst"},{"key":"10677_CR21","volume-title":"Intravenous immunoglobulin and intravenous methylprednisolone as optimal first line treatment in chronic inflammatory demyelinating polyneuropathy (CIDP)","author":"ISRCTN15893334","year":"2018","unstructured":"ISRCTN15893334 (2018) Intravenous immunoglobulin and intravenous methylprednisolone as optimal first line treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). BMC London"},{"issue":"4","key":"10677_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/jns.12242","volume":"22","author":"K Kuitwaard","year":"2017","unstructured":"Kuitwaard K, Fokkink WJR, Brusse E, Vrancken AFJE, Eftimov F, Notermans NC, van der Kooi AJ, Merkies ISJ, Jacobs BC, van Doorn PA (2017) Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 22(4):425\u2013432. https:\/\/doi.org\/10.1111\/jns.12242","journal-title":"J Peripher Nerv Syst"},{"key":"10677_CR23","first-page":"237","volume":"113","author":"F Eftimov","year":"2012","unstructured":"Eftimov F, van Schaik IN (2012) De behandeling van chronische inflammatoire demyeliniserende polyradiculoneuropathie. Tijdschrift voor Neurologie en Neurochirurgie 113:237\u2013244","journal-title":"Tijdschrift voor Neurologie en Neurochirurgie"},{"issue":"4","key":"10677_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","volume":"76","author":"SI van Nes","year":"2011","unstructured":"van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, Faber CG, Merkies IS (2011) Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76(4):337\u2013345. https:\/\/doi.org\/10.1212\/WNL.0b013e318208824b","journal-title":"Neurology"},{"issue":"9","key":"10677_CR25","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/1097-4598(200009)23:9<1393::aid-mus10>3.0.co;2-o","volume":"23","author":"IS Merkies","year":"2000","unstructured":"Merkies IS, Schmitz PI, Samijn JP, Meche FG, Toyka KV, van Doorn PA (2000) Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies. Muscle Nerve 23(9):1393\u20131401. https:\/\/doi.org\/10.1002\/1097-4598(200009)23:9%3c1393::aid-mus10%3e3.0.co;2-o","journal-title":"Muscle Nerve"},{"issue":"5","key":"10677_CR26","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1468-1331.2012.03851.x","volume":"20","author":"EK Vanhoutte","year":"2013","unstructured":"Vanhoutte EK, Latov N, Deng C, Hanna K, Hughes RA, Bril V, Dalakas MC, Donofrio P, van Doorn PA, Hartung HP, Merkies IS (2013) Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG\u2013the ICE study. Eur J Neurol 20(5):748\u2013755. https:\/\/doi.org\/10.1111\/j.1468-1331.2012.03851.x","journal-title":"Eur J Neurol"},{"issue":"11","key":"10677_CR27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, van der Meche FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 14(11):1103\u20131109. https:\/\/doi.org\/10.1002\/mus.880141111","journal-title":"Muscle Nerve"},{"issue":"11","key":"10677_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.nmd.2013.06.006","volume":"23","author":"EK Vanhoutte","year":"2013","unstructured":"Vanhoutte EK, Faber CG, Merkies IS, PeriNomS study group (2013) 196th ENMC international workshop: outcome measures in inflammatory peripheral neuropathies 8\u201310 February 2013, Naarden, The Netherlands. Neuromuscul Disord 23(11):924\u2013933. https:\/\/doi.org\/10.1016\/j.nmd.2013.06.006","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10677_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.nmd.2005.12.003","volume":"16","author":"IS Merkies","year":"2006","unstructured":"Merkies IS, Lauria G (2006) 131st ENMC international workshop: selection of outcome measures for peripheral neuropathy clinical trials 10\u201312 December 2004, Naarden, The Netherlands. Neuromuscul Disord 16(2):149\u2013156. https:\/\/doi.org\/10.1016\/j.nmd.2005.12.003","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10677_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1529-8027.2009.00238.x","volume":"14","author":"SI van Nes","year":"2009","unstructured":"van Nes SI, Vanhoutte EK, Faber CG, Garssen M, van Doorn PA, Merkies IS, PeriNom SSG (2009) Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale. J Peripher Nerv Syst 14(4):268\u2013278. https:\/\/doi.org\/10.1111\/j.1529-8027.2009.00238.x","journal-title":"J Peripher Nerv Syst"},{"issue":"10","key":"10677_CR31","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"issue":"23","key":"10677_CR32","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1212\/WNL.0000000000001044","volume":"83","author":"TH Draak","year":"2014","unstructured":"Draak TH, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol WL, Notermans NC, Nobile-Orazio E, Leger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, Hahn AF, Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS, PeriNom SSG (2014) Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology 83(23):2124\u20132132. https:\/\/doi.org\/10.1212\/WNL.0000000000001044","journal-title":"Neurology"},{"issue":"11","key":"10677_CR33","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/jnnp.2009.194324","volume":"81","author":"IS Merkies","year":"2010","unstructured":"Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C (2010) Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry 81(11):1194\u20131199. https:\/\/doi.org\/10.1136\/jnnp.2009.194324","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10677_CR34","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/jnnp-2014-309042","volume":"86","author":"K Kuitwaard","year":"2015","unstructured":"Kuitwaard K, Hahn AF, Vermeulen M, Venance SL, van Doorn PA (2015) Intravenous immunoglobulin response in treatment-naive chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 86(12):1331\u20131336. https:\/\/doi.org\/10.1136\/jnnp-2014-309042","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10677_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"R Hughes","year":"2001","unstructured":"Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A, Inflammatory Neuropathy C, Treatment G (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50(2):195\u2013201. https:\/\/doi.org\/10.1002\/ana.1088","journal-title":"Ann Neurol"},{"key":"10677_CR36","doi-asserted-by":"publisher","first-page":"CD002062","DOI":"10.1002\/14651858.CD002062.pub4","volume":"11","author":"RA Hughes","year":"2017","unstructured":"Hughes RA, Mehndiratta MM, Rajabally YA (2017) Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 11:CD002062. https:\/\/doi.org\/10.1002\/14651858.CD002062.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10677_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","volume":"17","author":"IN van Schaik","year":"2018","unstructured":"van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, group Ps, (2018) Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17(1):35\u201346. https:\/\/doi.org\/10.1016\/S1474-4422(17)30378-2","journal-title":"Lancet Neurol"},{"issue":"1","key":"10677_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/jns.12158","volume":"21","author":"MP Lunn","year":"2016","unstructured":"Lunn MP, Ellis L, Hadden RD, Rajabally YA, Winer JB, Reilly MM (2016) A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst 21(1):33\u201337. https:\/\/doi.org\/10.1111\/jns.12158","journal-title":"J Peripher Nerv Syst"},{"issue":"14","key":"10677_CR39","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1212\/WNL.0b013e31824e8f84","volume":"78","author":"F Eftimov","year":"2012","unstructured":"Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN, Predict (2012) Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 78(14):1079\u20131084. https:\/\/doi.org\/10.1212\/WNL.0b013e31824e8f84","journal-title":"Neurology"},{"issue":"4","key":"10677_CR40","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1529-8027.2009.00243.x","volume":"14","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA (2009) Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst 14(4):310\u2013315. https:\/\/doi.org\/10.1111\/j.1529-8027.2009.00243.x","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"10677_CR41","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1212\/wnl.53.8.1648","volume":"53","author":"IS Merkies","year":"1999","unstructured":"Merkies IS, Schmitz PI, Samijn JP, van der Meche FG, van Doorn PA (1999) Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 53(8):1648\u20131654. https:\/\/doi.org\/10.1212\/wnl.53.8.1648","journal-title":"Neurology"},{"issue":"6","key":"10677_CR42","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/mus.27038","volume":"62","author":"KL Gable","year":"2020","unstructured":"Gable KL, Attarian H, Allen JA (2020) Fatigue in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 62(6):673\u2013680. https:\/\/doi.org\/10.1002\/mus.27038","journal-title":"Muscle Nerve"},{"issue":"2","key":"10677_CR43","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/jns.12318","volume":"24","author":"B Bjelica","year":"2019","unstructured":"Bjelica B, Peric S, Bozovic I, Kacar A, Cobeljic M, Dejanovic I, Stevic Z, Basta I (2019) One-year follow-up study of neuropathic pain in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 24(2):180\u2013186. https:\/\/doi.org\/10.1111\/jns.12318","journal-title":"J Peripher Nerv Syst"},{"key":"10677_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-94-007-7596-1_3","volume-title":"Self-reported population health: an international perspective based on EQ-5D","author":"B Janssen","year":"2014","unstructured":"Janssen B, Szende A (2014) Population norms for the EQ-5D. In: Szende A, Janssen B, Cabases J (eds) Self-reported population health: an international perspective based on EQ-5D. Springer Netherlands, Dordrecht (NL), pp 19\u201330. https:\/\/doi.org\/10.1007\/978-94-007-7596-1_3"},{"issue":"1","key":"10677_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ene.12245","volume":"21","author":"M Mahdi-Rogers","year":"2014","unstructured":"Mahdi-Rogers M, McCrone P, Hughes RA (2014) Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. Eur J Neurol 21(1):34\u201339. https:\/\/doi.org\/10.1111\/ene.12245","journal-title":"Eur J Neurol"},{"issue":"6","key":"10677_CR46","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/ane.13322","volume":"142","author":"AK Ryltoft","year":"2020","unstructured":"Ryltoft AK, Al-Zuhairy A, Sindrup SH, Andersen H, Markvardsen LK (2020) Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin. Acta Neurol Scand 142(6):637\u2013640. https:\/\/doi.org\/10.1111\/ane.13322","journal-title":"Acta Neurol Scand"},{"issue":"9","key":"10677_CR47","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamaneurol.2020.0781","volume":"77","author":"JA Allen","year":"2020","unstructured":"Allen JA, Merkies ISJ, Lewis RA (2020) Monitoring clinical course and treatment response in chronic inflammatory demyelinating polyneuropathy during routine care: a review of clinical and laboratory assessment measures. JAMA Neurol 77(9):1159\u20131166. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0781","journal-title":"JAMA Neurol"},{"key":"10677_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-021-02838-w","author":"I Bozovic","year":"2021","unstructured":"Bozovic I, Peric M, Arsic Azanjac A, Palibrk A, Bulatovic I, Aleksic D, Peric S, Basta I (2021) Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Qual Life Res. https:\/\/doi.org\/10.1007\/s11136-021-02838-w","journal-title":"Qual Life Res"},{"issue":"1","key":"10677_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/mus.27089","volume":"63","author":"R Sadjadi","year":"2021","unstructured":"Sadjadi R, Peric S, Gwathmey K, Bozovic I, Aleksa P, Bjelica B, Burns T, Basta I (2021) Psychometric longitudinal evaluation of the Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) in patients with chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 63(1):84\u201388. https:\/\/doi.org\/10.1002\/mus.27089","journal-title":"Muscle Nerve"},{"issue":"3","key":"10677_CR50","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/jns.12396","volume":"25","author":"PE Doneddu","year":"2020","unstructured":"Doneddu PE, Mandia D, Gentile F, Gallia F, Liberatore G, Terenghi F, Ruiz M, Nobile-Orazio E (2020) Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. J Peripher Nerv Syst 25(3):238\u2013246. https:\/\/doi.org\/10.1111\/jns.12396","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10677_CR51","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/mus.26898","volume":"62","author":"PE Doneddu","year":"2020","unstructured":"Doneddu PE, Hadden RDM (2020) Daily grip strength response to intravenous immunoglobulin in chronic immune neuropathies. Muscle Nerve 62(1):103\u2013110. https:\/\/doi.org\/10.1002\/mus.26898","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10677-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10677-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10677-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T02:02:38Z","timestamp":1642816958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10677-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10677"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10677-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SB reports no disclosures; MB reports report grants from the Dutch Prinses Beatrix Spierfonds, during the conduct of the study; IL reports no disclosures; CB reports no disclosures; GvL reports no disclosures; MA reports no disclosures; RvV reports no disclosures; LW reports to have received research grants from Amsterdam UMC Neuroscience, Grifols and the GBS|CIDP Foundation for the study of disease activity biomarkers in CIDP; HL reports grants from the Dutch Prinses Beatrix Spierfonds, during the conduct of the study; HG has received research support from Prinses Beatrix Spierfonds, travel grants and speaker fee from Takeda\/ShireHG report; WvdP reports; IvS chaired a steering committee for a CSL-Behring study investigating the safety and efficacy of SCIg in CIDP and received departmental honoraria for serving on scientific advisory boards for CSL-Behring and Kedrion. He received departmental research support from The Netherlands Organization for Scientific Research, and from the Dutch Prinses Beatrix Fonds. All lecturing and consulting fees for INS were donated to the Stichting Klinische Neurologie, a local foundation that supports research in the field of neurological disorders. He served on the editorial board of the Cochrane Neuromuscular Disease Group, was a member of the organizing committee of the Inflammatory Neuropathy Consortium (INC), a standing committee of the Peripheral Nerve Society and was a member of the Scientific Board of the Kreuth III meeting on the optimal use of plasma-derived medicinal products, especially coagulation factors and normal immunoglobulins organized under the auspices of the European Directorate for the Quality of Medicines & HealthCare (EDQM); PvD reports grants from Takeda, during the conduct of the study; grants from Prinses Beatrix Spierfonds, grants from Sanquin Blood Supply, grants from Grifols, other from Hansa, Annexion, Argenx, CSL, and Octapharma, outside the submitted work; BJ reports grants from Dutch Prinses Beatrix Spierfond, during the conduct of the study; grants from Dutch Prinses Beatrix Spierfonds, Horizon 2020, GBS-CIDP Foundation International, Baxalta, Grifols, CSL Behring, Annexon and Hansa Biopharma outside the submitted work; FE reports grants from ZonMw (Dutch Governmental Agency), non-financial support from Sanquin Blood Supply, during the conduct of this study; He also reports grants from CSL Behring, Kedrion, Terumo BCT and Takeda Pharmaceutical Company, outside the submitted work. Grants were paid to the institution and are used for investigator-initiated studies within INCbase, an international CIDP registry. In addition, he received a consultancy fee from UCB pharma, paid to the institution, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Institutional review boards of all participating centers approved the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors are responsible for the correctness of the statements provided in the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}